PHINIA INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PHINIA INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $882.00M | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | $896.00M | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | $887.00M | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | $835.00M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $851.00M | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | $859.00M | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | $796.00M | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | $842.00M | Feb 28, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.48B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.40B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $3.50B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $3.35B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $3.23B | Feb 28, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $762.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $756.00M | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $186.00M | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | $177.00M | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | $189.00M | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | $172.00M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $188.00M | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | $201.00M | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | $158.00M | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | $174.00M | Feb 28, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $79.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $102.00M | Feb 12, 2026 |
| FY2023 | Sep 30, 2023 | ($1.00M) | Feb 28, 2024 |
| FY2024 | Dec 31, 2022 | $262.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $152.00M | Feb 28, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $254.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $259.00M | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $81.00M | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | $46.00M | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | $56.00M | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | $58.00M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $87.00M | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | $111.00M | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | $49.00M | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | $71.00M | Feb 28, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $105.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $112.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $108.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $104.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $132.00M | Feb 28, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $445.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $442.00M | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | $107.00M | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | $104.00M | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | $103.00M | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | $99.00M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $106.00M | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | $100.00M | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | $101.00M | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | $100.00M | Feb 28, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $312.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $308.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $250.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $303.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $147.00M | Feb 28, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.82B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.77B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $4.04B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $4.07B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $4.18B | Feb 28, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.23B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.19B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.15B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.43B | Feb 28, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $509.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $471.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $499.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $490.00M | Feb 28, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $44.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $9.00M | Feb 13, 2025 |
| FY2023 | Sep 30, 2023 | ($13.00M) | Feb 28, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $359.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $484.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $365.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $251.00M | Feb 28, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $970.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2024 | $988.00M | Feb 13, 2025 |
| FY2024 | Dec 31, 2023 | $723.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $26.00M | Feb 28, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | 1 | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | 1 | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | 1 | Feb 28, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 12, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | 1 | Feb 28, 2024 |
| FY2023 | Sep 30, 2022 | 1 | Feb 28, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Feb 28, 2024 |
| FY2023 | Mar 31, 2022 | 1 | Feb 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 37.92M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 41.64M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 46.16M | Feb 13, 2025 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $44.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $23.00M | Feb 12, 2026 |